Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of Zimlovisertib and Ritlecitinib in Healthy Adults
NCT03827668Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zimlovisertib in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoints: PF-06650833 Maximum Plasma Concentration, PF-06650833 Area Under the Curve and 2 more. Started Feb 2019; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03827668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827668.